Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been given an average rating of “Buy” by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $16.5556.

Several research firms have recently weighed in on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Truist Financial assumed coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company.

Inventiva Price Performance

NASDAQ IVA opened at $5.23 on Friday. The business’s fifty day moving average price is $5.44 and its 200-day moving average price is $5.39. Inventiva has a 1-year low of $2.85 and a 1-year high of $7.98.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. Research analysts anticipate that Inventiva will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC increased its stake in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares in the last quarter. Creative Planning purchased a new stake in shares of Inventiva in the 2nd quarter worth $32,000. Commonwealth Equity Services LLC increased its stake in shares of Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after purchasing an additional 12,704 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Inventiva in the 4th quarter worth $60,000. Finally, XTX Topco Ltd purchased a new stake in shares of Inventiva in the 4th quarter worth $84,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.